NDAINTRAPLEURALAEROSOLPriority Review
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SCLEROSOL (talc) is an intrapleural aerosol sclerosing agent approved in 1997 for pleurodesis in patients with malignant pleural effusion or recurrent spontaneous pneumothorax. Talc works by inducing inflammation and fibrosis of the pleural space to prevent fluid reaccumulation or air leakage. It is administered directly into the pleural cavity as a sterile powder via thoracoscopy or chest tube.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams should anticipate portfolio transition planning and resource reallocation within the next 1-2 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy
Started Nov 2025
167 enrolled
Gastroesophageal Reflux
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
Started May 2018
158 enrolled
Malignant Pleural EffusionRespiratory DiseaseCancer
Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management
Started Aug 2015
142 enrolled
Pleural Effusion, Malignant
Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes
Started May 2003
559 enrolled
Heartburn
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Started Mar 2002
150 enrolled
Colorectal CancerCarcinoma
Worked on SCLEROSOL at Innova Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.